Tumor necrosis factor (TNF-alpha) represents a family of cytokines which induce a wide number of biological effects that directly influence cell growth, cell differentiation, and programmed cell death. The prototype molecule TNF-alpha, is known to be involved in different pathological conditions including septic shock, rheumatoid arthritis, autoimmunity, HIV gene expression, cachexia, and cytotoxicity. Although the actions of TNF- alpha are mediated by two different cell surface receptors of M/r 55,000 and 75,000 daltons, little is known about how these receptors carry out signal transduction. Other growth factor and cytosine families convey their signals across the cell membrane by stimulating specific phosphorylation events after ligand binding. The two TNF receptors form a structurally related family that includes the Fas antigen, CD27, CD30, CD40 and OX40. The grant will test the hypothesis that TNF-alpha action requires additional signaling molecules, which are likely to interact either directly or indirectly with the TNF receptors. These activities may include tyrosine phosphorylation and hydrolysis of sphingomyelin to ceramide. Recent evidence indicates ceramide may act as a second messenger to promote programmed cell death by the TNT-alpha family of cytokines. This proposal will clone the mammalian sphingomyelinase enzyme that is believed to be responsible for TNF signal transduction and identify how ligand binding to this family of receptors leads to the activation of the sphingomyelinase activity. These studies will ultimately elucidate the molecular mechanisms that are responsible for TNF-alpha action during normal and disease states.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA056490-07
Application #
2837656
Study Section
Metabolic Pathology Study Section (MEP)
Program Officer
Mufson, R Allan
Project Start
1992-04-10
Project End
2000-11-30
Budget Start
1998-12-01
Budget End
1999-11-30
Support Year
7
Fiscal Year
1999
Total Cost
Indirect Cost
Name
New York University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
New York
State
NY
Country
United States
Zip Code
10016
Arevalo, Juan Carlos; Pereira, Daniela B; Yano, Hiroko et al. (2006) Identification of a switch in neurotrophin signaling by selective tyrosine phosphorylation. J Biol Chem 281:1001-7
Zampieri, Niccolo; Xu, Chong-Feng; Neubert, Thomas A et al. (2005) Cleavage of p75 neurotrophin receptor by alpha-secretase and gamma-secretase requires specific receptor domains. J Biol Chem 280:14563-71
Chittka, Alexandra; Arevalo, Juan Carlos; Rodriguez-Guzman, Maria et al. (2004) The p75NTR-interacting protein SC1 inhibits cell cycle progression by transcriptional repression of cyclin E. J Cell Biol 164:985-96
Murray, Simon S; Perez, Pilar; Lee, Ramee et al. (2004) A novel p75 neurotrophin receptor-related protein, NRH2, regulates nerve growth factor binding to the TrkA receptor. J Neurosci 24:2742-9
Jung, Kwang-Mook; Tan, Serena; Landman, Natalie et al. (2003) Regulated intramembrane proteolysis of the p75 neurotrophin receptor modulates its association with the TrkA receptor. J Biol Chem 278:42161-9
Kim, Albert H; Sasaki, Takehiko; Chao, Moses V (2003) JNK-interacting protein 1 promotes Akt1 activation. J Biol Chem 278:29830-6
Kim, Albert H; Yano, Hiroko; Cho, Han et al. (2002) Akt1 regulates a JNK scaffold during excitotoxic apoptosis. Neuron 35:697-709
Khursigara, G; Bertin, J; Yano, H et al. (2001) A prosurvival function for the p75 receptor death domain mediated via the caspase recruitment domain receptor-interacting protein 2. J Neurosci 21:5854-63
Dowling, P; Ming, X; Raval, S et al. (1999) Up-regulated p75NTR neurotrophin receptor on glial cells in MS plaques. Neurology 53:1676-82
Orlinick, J R; Vaishnaw, A; Elkon, K B et al. (1997) Requirement of cysteine-rich repeats of the Fas receptor for binding by the Fas ligand. J Biol Chem 272:28889-94

Showing the most recent 10 out of 15 publications